The Effect of Latanaprost on Intraocular Inflammation and Macular Edema

References

• Cook C, Foster P. Epidemiology of glaucoma: what’s new? Can J Ophthalmol. 2012;47(3):223–226.
   PubMed Web of Science ®Google Scholar
• Schehlein EM, Novack GD, Robin AL. New classes of glaucoma medications. Curr Opin Ophthalmol. 2017; 28(2):161-168.
   PubMed Web of Science ®Google Scholar
• Lim KS, Nau CB, O’Byrne MM, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008;115(5):790–5.e4.
   PubMed Web of Science ®Google Scholar
• Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost for glaucoma since its launch. Expert Opin Pharmacother. 2012;13(5):723–745.
   PubMedGoogle Scholar
• Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105(2):263–268.
   PubMed Web of Science ®Google Scholar
• Yeh PC, Ramanathan S. Latanoprost and clinically significant cystoid macular edema after uneventful phacoemulsification with intraocular lens implantation. J Cataract Refract Surg. 2002;28(10):1814–1818.
   PubMed Web of Science ®Google Scholar
• Lima MC, Paranhos A Jr., Salim S, et al. Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost. J Glaucoma. 2000;9(4):317–321.
   PubMed Web of Science ®Google Scholar
• Miyake K, Ota I, Maekubo K, et al. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol. 1999;117(1):34–40.
   PubMed Web of Science ®Google Scholar
• Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q, Yang YC. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes. Ophthalmology. 2016;123(2):316–323.
   PubMed Web of Science ®Google Scholar
• Ahad MA, McKee HD. Stopping prostaglandin analogues in uneventful cataract surgery. J Cataract Refract Surg. 2004;30(12):2644–2645.
   PubMed Web of Science ®Google Scholar
• Vadot E. Epidemiology of intermediate uveitis: a prospective study in Savoy. Dev Ophthalmol. 1992;23:33–34.
   PubMedGoogle Scholar
• Siddique SS, Suelves AM, Baheti U, Foster CS. Glaucoma and uveitis. Surv Ophthalmol. 2013;58(1):1–10.
   PubMed Web of Science ®Google Scholar
• Babu K, Murthy GJ. Cytomegalovirus anterior uveitis in immunocompetent individuals following topical prostaglandin analogues. J Ophthalmic Inflamm Infect. 2013;3(1):55.
   PubMedGoogle Scholar
• Arcieri ES, Santana A, Rocha FN, et al. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol. 2005;123(2):186–192.
   PubMedGoogle Scholar
• Toris CB, Camras CB, Yablonski ME, Brubaker RF. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol. 1997;41(Suppl 2):S69–75.
   PubMed Web of Science ®Google Scholar
• Kosaka T, Mishima HK, Kiuchi Y, Kataoka K. The effects of prostaglandins on the blood-ocular barrier. Jpn J Ophthalmol. 1995;39(4):368–376.
   PubMed Web of Science ®Google Scholar
• Hoyng PF, Rulo AH, Greve EL, et al. Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: a review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Surv Ophthalmol. 1997;41(Suppl 2):S83–8.
   PubMedGoogle Scholar
• Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111(10):1351–1358.
   PubMedGoogle Scholar
• Arcieri ES, Pierre Filho PT, Wakamatsu TH, Costa VP. The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension. Eye (Lond). 2008;22(2):179–183.
   PubMed Web of Science ®Google Scholar
• Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: is there a causal relation? Curr Opin Ophthalmol. 2000;11(2):94–100.
   PubMedGoogle Scholar
• Bhattacherjee P, Hammond B, Salmon JA, Eakins KE. Effect of lipoxygenase products on leukocyte accumulation in the rabbit eye. Adv Prostaglandin Thromboxane Leukot Res. 1982;9:325–330.
   PubMedGoogle Scholar
• Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand. 1999;77(6):668–672.
   PubMedGoogle Scholar
• Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102(12):1743–1752.
   PubMed Web of Science ®Google Scholar
• Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 1996;103(1):126–137.
   PubMed Web of Science ®Google Scholar
• Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996;103(1):138–147.
   PubMed Web of Science ®Google Scholar
• Mishima HK, Masuda K, Kitazawa Y, et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol. 1996;114(8):929–932.
   PubMedGoogle Scholar
• Linden C, Alm A. The effect on intraocular pressure of latanoprost once or four times daily. Br J Ophthalmol. 2001;85(10):1163–1166.
   PubMed Web of Science ®Google Scholar
• Fortuna E, Cervantes-Castaneda RA, Bhat P, et al. Flare-up rates with bimatoprost therapy in uveitic glaucoma. Am J Ophthalmol. 2008;146(6):876–882.
   PubMed Web of Science ®Google Scholar
• Chang JH, McCluskey P, Missotten T, et al. Use of ocular hypotensive prostaglandin analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema? Br J Ophthalmol. 2008;92(7):916–921.
   PubMed Web of Science ®Google Scholar
• Goldberg I, Li XY, Selaru P, Paggiarino D. A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2008;18(3):408–416.
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN, Kostakou A, Halkiadakis I, Chalkidou S, Papakonstantinou D, Georgopoulos G. Efficacy and safety of latanoprost in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol. 2009;247(6):775–780.
   PubMed Web of Science ®Google Scholar
• Selen F, Tekeli O, Yanik O. Assessment of the anterior chamber flare and macular thickness in patients treated with topical antiglaucomatous drugs. J Ocul Pharmacol Ther. 2017;33(3):170–175.
   PubMed Web of Science ®Google Scholar
• Astin M, Stjernschantz J, Selen G. Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994;59(4):401–407.
   PubMed Web of Science ®Google Scholar
• Stjernschantz J, Alm A. Latanoprost as a new horizon in the medical management of glaucoma. Curr Opin Ophthalmol. 1996;7(2):11–17.
   PubMedGoogle Scholar
• Russo A, Riva I, Pizzolante T, et al. Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review. Clin Ophthalmol. 2008;2(4):897–905.
   PubMedGoogle Scholar
• Peyman GA, Bennett TO, Vlchek J. Effects of intravitreal prostaglandins on retinal vasculature. Ann Ophthalmol. 1975;7(2):279–288.
   PubMedGoogle Scholar
• Rowe JA, Hattenhauer MG, Herman DC. Adverse side effects associated with latanoprost. Am J Ophthalmol. 1997;124(5):683–685.
   PubMed Web of Science ®Google Scholar
• Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol. 1998;126(4):602–604.
   PubMed Web of Science ®Google Scholar
• Nouri-Mahdavi K, Javadi MA, Jafarinasab MR. Immunologic corneal graft rejection after administration of topical latanoprost: a report of two patients. J Ophthalmic Vis Res. 2011;6(2):127–130.
   PubMedGoogle Scholar
• Brasil OF, Brasil MV, Ventura MP, Maia HS. Bilateral and simultaneous cystoid macular edema associated with latanoprost use: report of two cases. Arq Bras Oftalmol. 2010;73(2):186–188.
   PubMed Web of Science ®Google Scholar
• Panteleontidis V, Detorakis ET, Pallikaris IG, Tsilimbaris MK. Latanoprost-dependent cystoid macular edema following uncomplicated cataract surgery in Pseudoexfoliative eyes. Ophthalmic Surg Lasers Imaging. 2010. doi:10.3928/15428877-20100215-91.
   PubMedGoogle Scholar
• Ozdemir H, Karacorlu M, Karacorlu SA. Serous detachment of macula in cystoid macular edema associated with latanoprost. Eur J Ophthalmol. 2008;18(6):1014–1016.
   PubMed Web of Science ®Google Scholar
• Grigoropoulos VG, Emfietzoglou I, Nikolaidis P, Theodossiadis PG, Theodossiadis GP. Cystoid macular oedema within 24 h after a single application of latanoprost. Int Ophthalmol. 2009;29(4):257–259.
   PubMedGoogle Scholar
• Baba T, Nagayama M, Ohtsuki H, Hirooka K, Shiraga F. Macular edema associated with latanoprost use in a patient with idiopathic juxtafoveal retinal telangiectasis. Jpn J Ophthalmol. 2008;52(1):68–70.
   PubMed Web of Science ®Google Scholar
• Esquenazi S. Cystoid macular edema in a pseudophakic patient after switching from latanoprost to BAK-free travoprost. J Ocul Pharmacol Ther. 2007;23(6):567–570.
   PubMed Web of Science ®Google Scholar
• Dhingra N, Morgan JE. Pseudophakic cystoid macular oedema: 30 months after latanoprost challenge. Eye (Lond). 2007;21(2):269–271.
   PubMed Web of Science ®Google Scholar
• Kruse P, Rieck P, Sherif Z, Liekfeld A. [Cystoid macular edema in a pseudophakic patient after several glaucoma procedures. Is local therapy with bimatoprost the reason?]. Klin Monbl Augenheilkd. 2006;223(6):534–537.
   PubMed Web of Science ®Google Scholar
• Carrillo MM, Nicolela MT. Cystoid macular edema in a low-risk patient after switching from latanoprost to bimatoprost. Am J Ophthalmol. 2004;137(5):966–968.
   PubMed Web of Science ®Google Scholar
• Jager M, Jonas JB. Cystoid macular edema associated with latanoprost therapy in a pseudophakic vitrectomized patient after removal of silicone oil endotamponade. Eur J Ophthalmol. 2003;13(2):221–222.
   PubMed Web of Science ®Google Scholar
• Wardrop DR, Wishart PK. Latanoprost and cystoid macular oedema in a pseudophake. Br J Ophthalmol. 1998;82(7):843–844.
   PubMed Web of Science ®Google Scholar
• Tokunaga T, Kashiwagi K, Saito J, et al. A case of cystoid macular edema associated with latanoprost ophthalmic solution. Jpn J Ophthalmol. 2002;46(6):656–659.
   PubMed Web of Science ®Google Scholar
• Moroi SE, Gottfredsdottir MS, Schteingart MT, et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology. 1999;106(5):1024–1029.
   PubMed Web of Science ®Google Scholar
• Chebil A, Moslem S, Maamouri R, El Matri L. Spectral-domain optical coherence tomography in macular edema associated with latanoprost. Tunis Med. 2015;93(10):656–657.
   PubMedGoogle Scholar
• Heier JS, Steinert RF, Frederick AR Jr. Cystoid macular edema associated with latanoprost use. Arch Ophthalmol. 1998;116(5):680–682.
   PubMedGoogle Scholar
• Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol. 1998;126(1):134–135.
   PubMed Web of Science ®Google Scholar
• Thorne JE, Maguire AM, Lanciano R. CME and anterior uveitis with latanoprost use. Ophthalmology. 1998;105(11):1981–1983.
   PubMedGoogle Scholar
• Gaddie IB, Bennett DW. Cystoid macular edema associated with the use of latanoprost. J Am Optom Assoc. 1998;69(2):122–128.
   PubMedGoogle Scholar
• Wand M, Gaudio AR, Shields MB. Latanoprost and cystoid macular edema in high-risk aphakic or pseudophakic eyes. J Cataract Refract Surg. 2001;27(9):1397–1401.
   PubMed Web of Science ®Google Scholar
• Wand M, Gaudio AR. Cystoid macular edema associated with ocular hypotensive lipids. Am J Ophthalmol. 2002;133(3):403–405.
   PubMed Web of Science ®Google Scholar
• Cheng JW, Xi GL, Wei RL, Cai J-P, Li Y. Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: a systematic review and meta-analysis. Curr Ther Res Clin Exp. 2009;70(4):335–350.
   PubMed Web of Science ®Google Scholar
• Cheng JW, Wei RL. Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure. Clin Ther. 2008;30(4):622–632.
   PubMed Web of Science ®Google Scholar
• Halpern DL, Pasquale LR. Cystoid macular edema in aphakia and pseudophakia after use of prostaglandin analogs. Semin Ophthalmol. 2002;17(3–4):181–186.
   PubMedGoogle Scholar
• Steinert RF, Puliafito CA, Kumar SR, Dudak SD, Patel S. Cystoid macular edema, retinal detachment, and glaucoma after Nd: yAGlaser posterior capsulotomy. Am J Ophthalmol. 1991;112(4):373–380.
   PubMed Web of Science ®Google Scholar
• Moghimi S, Zandian M, Latifi G, et al. Topical latanoprost does not cause macular thickening after uncomplicated cataract surgery. J Ophthalmic Vis Res. 2012;7(4):289–294.
   PubMedGoogle Scholar
• Watanabe K, Hayasaka S, Hayasaka Y, et al. Cystoid macular edema associated with latanoprost use in a pseudophakic eye with a history of surgical complications. Jpn J Ophthalmol. 2003;47(1):110–112.
   PubMed Web of Science ®Google Scholar
• Avakian A, Renier SA, Butler PJ. Adverse effects of latanoprost on patients with medically resistant glaucoma. Arch Ophthalmol. 1998;116(5):679–680.
   PubMedGoogle Scholar
• Kolker AE, Becker B. Epinephrine maculopathy. Arch Ophthalmol. 1968;79(5):552–562.
   PubMedGoogle Scholar
• Mehelas TJ, Kollarits CR, Martin WG. Cystoid macular edema presumably induced by dipivefrin hydrochloride (Propine). Am J Ophthalmol. 1982;94(5):682.
   PubMed Web of Science ®Google Scholar
• Hesse RJ, Swan JL 2nd. Aphakic cystoid macular edema secondary to betaxolol therapy. Ophthalmic Surg. 1988;19(8):562–564.
   PubMedGoogle Scholar
• Miyake K, Ota I, Ibaraki N, et al. Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia. Arch Ophthalmol. 2001;119(3):387–394.
   PubMedGoogle Scholar
• Miyake K, Ibaraki N, Goto Y, et al. ESCRS Binkhorst lecture 2002: pseudophakic preservative maculopathy. J Cataract Refract Surg. 2003;29(9):1800–1810.
   PubMed Web of Science ®Google Scholar
• Altintas O, Yuksel N, Karabas VL, Demirci G. Cystoid macular edema associated with latanoprost after uncomplicated cataract surgery. Eur J Ophthalmol. 2005;15(1):158–161.
   Web of Science ®Google Scholar
• Plange N, Bienert M, Remky A, Arend KO. Optic disc fluorescein leakage and intraocular pressure in primary open-angle glaucoma. Curr Eye Res. 2012;37(6):508–512.
   PubMed Web of Science ®Google Scholar
• Goto Y, Ibaraki N, Miyake K. Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol. Arch Ophthalmol. 2003;121(6):835–839.
   PubMedGoogle Scholar
• Abe RY, Zacchia RS, Santana PR, Costa VP. Effects of benzalkonium chloride on the blood-aqueous and blood-retinal barriers of pseudophakic eyes. J Ocul Pharmacol Ther. 2014;30(5):413–418.
   PubMed Web of Science ®Google Scholar
• Matsuura K, Uotani R, Terasaka Y. Subtenon triamcinolone injection for postoperative cystoid macular edema associated with tafluprost. Clin Ophthalmol. 2013;7:1525–1528.
   PubMedGoogle Scholar
• Jamal KN, Callanan DG. The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol. 2009;3:381–390.
   PubMedGoogle Scholar
• Guo S, Patel S, Baumrind B, et al. Management of pseudophakic cystoid macular edema. Surv Ophthalmol. 2015;60(2):123–137.
   PubMed Web of Science ®Google Scholar
• Bradford JD, Wilkinson CP, Bradford RH Jr. Cystoid macular edema following extracapsular cataract extraction and posterior chamber intraocular lens implantation. Retina. 1988;8(3):161–164.
   PubMed Web of Science ®Google Scholar
• O’Brien TP. Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Med Res Opin. 2005;21(7):1131–1137.
   PubMed Web of Science ®Google Scholar
• Hoffman RS, Braga-Mele R, Donaldson K, et al. Cataract surgery and nonsteroidal antiinflammatory drugs. J Cataract Refract Surg. 2016;42(9):1368–1379.
   PubMed Web of Science ®Google Scholar